Is Castle Biosciences, Inc. overvalued or undervalued?

Sep 20 2025 06:11 PM IST
share
Share Via
As of May 5, 2025, Castle Biosciences, Inc. is considered a risky investment due to its overvaluation, reflected in a Price to Book Value of 1.15, an unfavorable EV to EBITDA ratio of 8.54, a negative ROCE of -7.81%, and significant underperformance compared to the S&P 500.
As of 5 May 2025, the valuation grade for Castle Biosciences, Inc. has moved from attractive to risky, indicating a shift in perception regarding its investment potential. The company appears to be overvalued, given its current Price to Book Value of 1.15, an EV to EBITDA ratio of 8.54, and a negative ROCE of -7.81%. In comparison to peers, Castle's EV to EBITDA ratio is significantly less favorable than that of Atrion Corp., which has a ratio of 26.2211, and Silk Road Medical, Inc., with a ratio of -18.1243.

The stock has underperformed relative to the S&P 500, with a year-to-date return of -11.97% compared to the index's 12.22%, and a 1-year return of -22.73% versus 17.14% for the S&P 500. This trend reinforces the notion that Castle Biosciences, Inc. is overvalued in the current market context.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News